To study the biological molecules called biomarkers of inflammation raised in blood in patients of chronic obstructive pulmonary disease who are above 40 years and how they are connected to co-morbid conditions in same patients.

Study of inflammatory biomarkers in COPD and their association with co-morbidities - Nil

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2024/06/068234

Enrollment

Registered

2024-06-03

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecified

Interventions

Intervention1: NIL: NA Control Intervention1: NIL: NA

Eligibility

Inclusion criteria

Inclusion criteria: Patients who are diagnosed cases of COPD in the department of respiratory medicine at AVBRH and age above 40 years

Exclusion criteria

Exclusion criteria: Patients not willing to give consent and non cooperative patients. Patients having any connective tissue disorder like rheumatoid arthritis. Patients having COPD asthma overlap.

Design outcomes

Primary

Measure	Time frame
The primary outcome of this study is to determine the levels of inflammatory biomarkers in patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD). Specifically, the focus is on measuring the levels of CRP (C-reactive protein), IL-6 (Interleukin-6), TNF-ALFA (Tumor Necrosis Factor Alpha), and fibrinogen in the blood samples of COPD patients. These biomarkers are chosen due to their established association with inflammation, and their levels may provide insights into the inflammatory processes occurring in COPD. Timepoint: Assessment will be done every 6 months	—

Measure

Time frame

The primary outcome of this study is to determine the levels of inflammatory biomarkers in patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD). Specifically, the focus is on measuring the levels of CRP (C-reactive protein), IL-6 (Interleukin-6), TNF-ALFA (Tumor Necrosis Factor Alpha), and fibrinogen in the blood samples of COPD patients. These biomarkers are chosen due to their established association with inflammation, and their levels may provide insights into the inflammatory processes occurring in COPD. Timepoint: Assessment will be done every 6 months

—

Secondary

Measure	Time frame
NILTimepoint: N/A	—

Countries

India

Contacts

Public ContactAishwarya Kishor Kedar

Jawaharlal Nehru Medical College,Sawangi Meghe Wardha

drulhasjadhav@gmail.com9284196369

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026